Patient Financing Done Right: Cherry, Wisetack, PatientFi, and the True Cost of 'Free' Financing

The mechanics are simple and worth saying plainly, because the word "financing" makes it sound free to the practice. A third-party platform pays you for the treatment up front and collects from the patient over time, taking a fee — typically a percentage of the transaction — for assuming that role and the credit risk. You get paid now; the patient gets a payment plan; the platform's cut comes off your top. It's a merchant fee, structurally similar to the cost of accepting a card, just larger and attached to a bigger transaction. There is no version of this where the practice pays nothing; the only question is whether what you're paying for is worth it.

The math that decides "worth it"

Financing earns its fee when it converts a sale that genuinely would not have happened at full price up front. A patient who walks because they can't manage the lump sum, then books because financing made the monthly workable, is incremental revenue you'd otherwise have lost entirely — and a percentage fee on a sale you'd have made zero on is obviously worth paying. That's financing doing its job: expanding access, enabling larger plans and packages, growing your average ticket.

It stops being worth it the moment it's applied to patients who'd have paid in full anyway. Default every checkout to financing and you're now paying a fee on transactions that needed no help — which is just a discount you didn't decide to give, spread quietly across your whole book. The same tool that expands your market on the right patient subsidizes a giveaway on the wrong one, and the difference is entirely in whether you offered it deliberately or reflexively.

Choosing among the platforms

The platforms differ in ways that matter to your specific economics: fee structures, approval rates and criteria (how many of your patients actually get approved, and at what terms), the patient experience, and how they handle promotional or deferred-interest periods. The right choice depends on your average ticket, your patient base's credit profile, and which fee-versus-approval tradeoff fits — a higher approval rate can be worth a higher fee if it converts more of your patients, or not, depending on your numbers. Compare the all-in cost against the conversion you actually get, not the marketing claims, and don't assume the platform with the lowest headline fee is the cheapest once approval rates are in the math.

Present it as an enabler, not a default

The behavioral discipline is to position financing where it expands the sale — larger treatment plans, packages, the bigger device-treatment series — and to offer it intentionally rather than blanketing it across every transaction. Deliberate use grows average ticket and widens access to patients who'd otherwise be priced out. Reflexive use erodes margin across the patients who never needed it. Same tool, opposite outcomes, and the only variable is whether your team reaches for it on purpose.

What to do

• Treat the financing fee as a cost of the sale, not free money, and decide where that cost earns its keep.
• Deploy financing where it converts treatment that wouldn't happen at full price up front — bigger plans, packages, series — not as a universal checkout default.
• Compare platforms on all-in cost and real approval rates for your patient base, not headline fees.
• Train the team to offer it intentionally as an enabler of larger plans, so you're expanding your market rather than quietly discounting your book.

Financing genuinely can grow a practice — it lets people say yes to treatment they want and can't pay for at once, and it lifts your average ticket when it's pointed at the right sales. The trap is forgetting that it costs something and letting it become the reflexive answer at every checkout, at which point you've turned a market-expansion tool into a margin leak. Use it on purpose, on the sales it actually unlocks, and it pays for itself. Use it by default, and you're paying a fee to discount business you already had.